J&J targets rare maternal-fetal diseases: 'We're going for this. No one else has.'

Just once in history has a drug been approved in maternal fetal immunology, specifically, in hemolytic disease of the fetus and newborn (HDFS) and fetal and neonatal alloimmune thrombocytopenia (FNAIT).

“And it was approved in 1968," says Katie Abouzahr, M.D., Johnson & Johnson’s vice president and autoantibody and maternal fetal immunology disease area leader, in an interview with Fierce Biotech. “That program was revolutionary."